Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

493
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer.

Cancer research·2026
Same author

ResMap: A community resource for systematic mapping of therapy-persistent residual cancer cell dependencies across contexts.

Science advances·2026
Same author

Suppression of PP2A-B56α drives EMT in EGFR mutant non-small cell lung cancer.

Oncogene·2026
Same author

ApoFLARE: a luminescent reporter for direct quantification of APOBEC3A editing activity.

bioRxiv : the preprint server for biology·2026
Same author

Prevalence and Actionability of MTAP Loss in Oncogene-Driven Lung Cancer.

bioRxiv : the preprint server for biology·2026
Same author

MUCIN 1 confers inflammatory memory of tyrosine kinase inhibitor resistance in non-small cell lung cancer.

Signal transduction and targeted therapy·2025
Same journal

IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial.

Nature cancer·2026
Same journal

GPNMB-directed CAR-T cell therapies for solid tumors.

Nature cancer·2026
Same journal

GPNMB-directed CAR T cell therapy against MiT/TFE-family fusion-driven solid tumors.

Nature cancer·2026
Same journal

Long-term outcomes of adjuvant metronomic capecitabine in locoregionally advanced nasopharyngeal carcinoma: a randomized, controlled, multicenter, phase 3 study.

Nature cancer·2026
Same journal

Inhibition of ADSS2-mediated de novo AMP biosynthesis re-sensitizes acute myeloid leukemia to BH3 mimetics.

Nature cancer·2026
Same journal

GABA signaling activation drives glioblastoma progression in female mice through myeloid-derived suppressor cells.

Nature cancer·2026
查看所有相关文章

相关实验视频

Updated: Jun 14, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.2K

针对性治疗-持续的残留疾病.

Xiaoxiao Sun1, Lani F Wu2, Steven J Altschuler3

  • 1Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.

Nature cancer
|September 17, 2024
PubMed
概括
此摘要是机器生成的。

在残留疾病中向治疗持久的癌细胞可以提高抗癌治疗的有效性和耐久性. 克服临床实施的障碍对于开发针对获得的耐药性和疾病复发的新策略至关重要.

更多相关视频

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

14.2K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

398

相关实验视频

Last Updated: Jun 14, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.2K
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

14.2K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

398

科学领域:

  • 在瘤学瘤学.
  • 癌症治疗 癌症治疗
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 获得的耐药性导致疾病复发,限制了全身抗癌药物的有效性.
  • 在残留疾病中持久的癌细胞是当前癌症疗法的关键挑战.
  • 针对这些持久细胞提供了一种改善治疗耐久性的策略.

研究的目的:

  • 讨论针对治疗持续的残留疾病的复杂性.
  • 概述了开发针对残留癌症的临床策略的关键步骤.
  • 解决在瘤学中实施持久导向方法的障碍.

主要方法:

  • 对治疗持久细胞的临床前发现的审查.
  • 针对残留疾病的临床复杂性的分析.
  • 讨论开发持续性定向疗法的挑战.

主要成果:

  • 在将持久导向方法转化为临床实践方面存在重大障碍.
  • 临床前策略有希望,但需要进一步开发以获得临床应用.
  • 了解和克服抵抗机制至关重要.

结论:

  • 开发临床策略以针对治疗持续的残留疾病是必不可少的.
  • 解决当前的复杂性是提高癌症治疗疗效和耐久性的关键.
  • 需要进一步的研究和临床开发来克服实施障碍.